https://www.yiliao.com/index.php?action=history&feed=atom&title=Cobimetinib
Cobimetinib - 版本历史
2026-04-19T23:07:43Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Cobimetinib&diff=313521&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T06:30:14Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[考比替尼]]([[Cobimetinib]])</strong>，商品名为<strong>[[考比替]]([[Cotellic]])</strong>，研发代码为<strong>[[GDC-0973]]</strong>，是由[[罗氏]]([[Roche]])研发的一种口服、高选择性<strong>[[MEK1/2激酶抑制剂]]</strong>。在2026年的精准诊疗体系中，[[考比替尼]]是调控<strong>[[MAPK/ERK]]</strong>信号通路的关键药物，主要与[[BRAF]]抑制剂<strong>[[佐博伏]]([[维莫非尼]])</strong>联合使用。这种“双靶向垂直阻断”策略旨在克服单药[[BRAF]]抑制剂引起的反馈性通路激活，显着延长了携带<strong>[[BRAF V600]]</strong>突变的晚期<strong>[[黑色素瘤]]</strong>患者的无进展生存期([[PFS]])，并已被探索用于[[组织细胞增生症]]等罕见病。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">考比替尼 (Cobimetinib)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">考比替·Cotellic·GDC-0973·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Cobimetinib Chemical Structure: A highly potent allosteric inhibitor</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[MEK1]]/[[MEK2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5604/5605</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6840/6842</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q02750/P36507</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">531.3Da(富马酸盐)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药剂量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">60mg QD(连服21天停7天)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[罗氏]]/[[Genentech]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">黑色素瘤双靶标准方案组分</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：变构抑制与垂直阻断协同</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[考比替尼]]作为一种强效的<strong>[[变构抑制剂]]</strong>，其药理优势在于对[[MEK]]激酶的高亲和力。2026年分子生物学共识将其临床效能归结为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>拦截 MAPK 级联：</strong> 在[[BRAF]]突变驱动的细胞中，信号通过[[RAF]]向下传导至[[MEK]]。[[考比替尼]]能特异性结合[[MEK1]]和[[MEK2]]，阻止其磷酸化下游<strong>[[ERK1/2]]</strong>蛋白，从而使促增殖信号“断流”。</li><br />
<li style="margin-bottom: 12px;"><strong>中和反馈激活：</strong> 单药[[BRAF]]抑制剂常导致通路代偿性重启。联用[[考比替尼]]可有效压制这种反馈，显著延迟耐药的发生。</li><br />
<li style="margin-bottom: 12px;"><strong>减低毒性悖论：</strong> [[考比替尼]]能抑制[[BRAF]]抑制剂在正常皮肤细胞中引发的<strong>[[悖论性激活]]</strong>，从而将继发性皮肤鳞状细胞癌的风险降低了约70%以上。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据与生存获益矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评价)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/响应获益</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[coBRIM]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">一线[[BRAF V600]]黑色素瘤；联合[[维莫非尼]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>PFS 达 12.3个月</strong>；客观缓解率([[ORR]])达 70%。确立一线金标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[IMspire150]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">三联疗法：[[考比]]+[[维莫]]+[[阿替利珠单抗]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026随访确认：在特定高瘤负荷人群中展现更持久的响应。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[罕见病研究]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对[[组织细胞增生症]]([[ECD]]/[[LCH]])。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>ORR 接近 90%</strong>。确立了[[MAPK]]通路驱动罕见病的首选靶向路径。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从节律给药到精准监护</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[考比替尼]]的临床应用遵循2026年“**[[安全性前置化干预]]**”原则：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>服21停7节律：</strong> 2026版指南强调：必须严格遵守28天周期（服21天，停7天）。这一设计是为了在停药期缓解[[MEK]]抑制引起的累积毒性，如<strong>[[腹泻]]</strong>及<strong>[[肝酶升高]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>眼部副作用防治：</strong> [[考比替尼]]可能诱发<strong>[[浆液性视网膜病变]]([[RPED]])</strong>。2026临床共识建议：一旦患者自述视力模糊，应立即行[[OCT]]检查。多数轻中度病例通过剂量调节可逆转。</li><br />
<li style="margin-bottom: 12px;"><strong>联合用药的光敏防护：</strong> 与[[维莫非尼]]联用时，由于二者均具有显著的光毒性，2026规范强制要求：患者需全天候执行物理+化学双重物理防晒。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[MEK1/2]]：</strong> 信号通路中的闸门激酶，考比替尼的直接靶位。</li><br />
<li style="margin-bottom: 8px;"><strong>[[垂直阻断]]([[Vertical Blockade]])：</strong> 同时抑制RAF及MEK，彻底封死通路。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CK升高]]([[CPK]])：</strong> 考比替尼常见的无症状副反应，需监测肌肉毒性。</li><br />
<li style="margin-bottom: 8px;"><strong>[[阿替利珠单抗]]：</strong> 常用于“IO+双靶”三联方案中的免疫药物组分。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Larkin J, et al. (2014/2026Update).</strong> <em>Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma (coBRIM Trial).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项里程碑式研究验证了联合治疗优于单靶点封锁的生物学假说，改写了全球黑色素瘤诊疗格局。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[The Lancet Oncology]]. (2025/2026Revision).</strong> <em>Systemic Management of MAPK-driven Histiocytic Disorders: Cotellic as a Paradigm.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年修订版共识正式将考比替尼列为特定难治性组织细胞病的优先靶向方案。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
考比替尼 (Cotellic) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MEK1]]•[[MEK2]]•[[ERK]]•[[BRAF V600]]•[[C-RAF]]•[[CYP3A4]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[考比替尼]]•[[维莫非尼]]•[[曲美替尼]]•[[比尼替尼]]•[[阿替利珠单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Roche]]•[[罗氏]]•[[Genentech]]•[[SinoCellGene协作]]•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[三联强化治疗]]•[[视网膜毒性机制]]•[[组织细胞病靶向]]•[[间歇给药优化]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166